Thomas J. Walsh, MD
Selinexor (Xpovio), an FDA-approved drug for the treatment of patients with relapsed/refractory multiple myeloma, is being evaluated in a global randomized clinical trial as a potential treatment for hospitalized patients with severe COVID-19.1
"One of the most important aspects of COVID-19 is the marked pulmonary inflammation with high levels of cytokines such as IL6, IL1, IFNg and others. Along these lines, selinexor and other SINE compounds have demonstrated potent anti-inflammatory activity through the inhibition of NF-kB, leading to reductions in all of these cytokines in a variety of models, and this may be particularly beneficial to hospitalized patients with COVID-19,” the company explained.
Thomas J. Walsh, MD, professor of Medicine, Pediatrics, and Microbiology & Immunology, Weill Cornell Medicine, Cornell University, commented in the press release on the decision to explored selinexor for COVID-19.
... to read the full story